Entry Detail



General Information

Database ID:exR0274815
RNA Name:hsa-miR-432-5p
RNA Type:miRNA
Chromosome:chr14
Starnd:+
Coordinate:
Start Site(bp):100884496End Site(bp):100884518
External Links:hsa-miR-432-5p



Disease Information

Disease Name:Breast Cancer
Disease Category:Cancers
MeSH ID:D001943
Type:Neoplasms/Breast Neoplasms
Alias:Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast



Expression Detail

GEO ID:GSE22981
Description:Circulating miRNAs as biomarkers and potential functional mediators of early stage breast cancer
Experimental Design:Cancer vs Control
Case Disease Type:Breast Cancer
Case Disease SubType:Early satge breast cancer
Case Sample:Breast Cancer
Control Sample:Control
Number of Case:20
Number of Control:20
Number of Samples:40





Regulatory Relationship

mRNA targets:
Gene SymbolChromosomeStart Site(bp)End Site(bp)Strand
ABL1
chr9
130713016
130887675
+
ANXA2
chr15
60347134
60402883
-
ATP5MC3
chr2
175176258
175184607
-
BLCAP
chr20
37492472
37527931
-
CA12
chr15
63321378
63381846
-
CALM1
chr14
90396502
90408268
+
CELSR2
chr1
109249539
109275751
+
CHTF8
chr16
69118010
69132578
-
DNAJC13
chr3
132417502
132539032
+
EPB41
chr1
28887091
29120046
+
FADS2
chr11
61792980
61867354
+
FN1
chr2
215360440
215436073
-
GGA3
chr17
75236599
75262363
-
GNAI2
chr3
50226292
50259362
+
HMBOX1
chr8
28890395
29064764
+
IGF1R
chr15
98648539
98964530
+
IPO9
chr1
201829149
201884291
+
KDM3B
chr5
138352685
138437028
+
MFHAS1
chr8
8783354
8893630
-
NAPEPLD
chr7
103099776
103149560
-
PHC3
chr3
170086732
170181749
-
PRELID3B
chr20
59033145
59042809
-
PTCD3
chr2
86106223
86142157
+
RASA1
chr5
87267883
87391931
+
SETD7
chr4
139495941
139606699
-
STAMBP
chr2
73828916
73873659
+
TMEM63A
chr1
225845536
225882380
-
TOB2
chr22
41433494
41446801
-
ZBTB34
chr9
126860665
126885878
+
ZNF12
chr7
6688433
6706947
-
miRNA targets:NA
circRNA targets:
circRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
hsa_circ_0001454
chr4
154524454
154533552
+
hsa_circ_0001349
chr3
152132729
152150709
+
lncRNA targets:
lncRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
AC009133.5
chr16
29808679
29812227
+
AC016876.2
chr17
7581964
7584086
-
AC068768.1
chr12
123262060
123262402
+
AC239868.1
chr1
149861271
149862504
+
KCNQ1OT1
chr11
2608328
2699994
-
LINC00649
chr21
33915534
33977691
+
NEAT1
chr11
65422774
65445540
+
PCBP2-OT1
chr12
53464468
53465057
+
SNHG16
chr17
76557764
76565348
+
XIST
chrX
73820649
73852723
-
ZFAS1
chr20
49278178
49299600
+
Display:



Experiment Detail

GEO ID:GSE22981
Sample Source:Blood
Source Fraction:Plasma
Platform:GPL8179
Method:Microarray
Num of detected RNA Type:1
Num of detected RNAs of this Type:801
Sample treatment protocol:NA
RNA Extract protocol:Total RNA, including miRNA from plasma, was isolated using the miRNeasy kit (Qiagen) with minor modifications.
RNA library preparation protocol:Two hundred ng of total RNA from each sample were labeled and hybridized on Human v2 MicroRNA Expression BeadChips (Cat. no. MI-102-1024; Illumina).



Reference

PMID:21060830
Title:A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer
Author:Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu SBACKGROUND: To date, there are no highly sensitive and specific minimally invasive biomarkers for detection of breast cancer at an early stage. The occurrence of circulating microRNAs (miRNAs) in blood components (including serum and plasma) has been repeatedly observed in cancer patients as well as healthy controls. Because of the significance of miRNA in carcinogenesis, circulating miRNAs in blood may be unique biomarkers for early and minimally invasive diagnosis of human cancers. The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers. METHODOLOGY/PRINCIPAL FINDINGS: Using microarray-based expression profiling followed by Real-Time quantitative Polymerase Cycle Reaction (RT-qPCR) validation, we compared the levels of circulating miRNAs in plasma samples from 20 women with early stage breast cancer (10 Caucasian American (CA) and 10 African American (AA)) and 20 matched healthy controls (10 CAs and 10 AAs). Using the significance level of p<0.05 constrained by at least two-fold expression change as selection criteria, we found that 31 miRNAs were differentially expressed in CA study subjects (17 up and 14 down) and 18 miRNAs were differentially expressed in AA study subjects (9 up and 9 down). Interestingly, only 2 differentially expressed miRNAs overlapped between CA and AA study subjects. Using receiver operational curve (ROC) analysis, we show that not only up-regulated but also down-regulated miRNAs can discriminate patients with breast cancer from healthy controls with reasonable sensitivity and specificity. To further explore the potential roles of these circulating miRNAs in breast carcinogenesis, we applied pathway-based bioinformatics exploratory analysis and predicted a number of significantly enriched pathways which are predicted to be regulated by these circulating miRNAs, most of which are involved in critical cell functions, cancer development and progression. CONCLUSIONS: Our observations from this pilot study suggest that the altered levels of circulating miRNAs might have great potential to serve as novel, noninvasive biomarkers for early detection of breast cancer.
Journal:PLoS One. 2010 Oct 29;5(10):e13735.
Description:The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers.